Insider Cluster (3 insiders) ·Filed Jul 14, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago
Insider cluster: 3 insiders, $0.3M total
Actionable Insight • Neutral

This cluster is routine and non-material. The CEO's sales are clearly tied to option exercise and tax withholding, not a bearish view. No trading action warranted; monitor for any material corporate events (e.g., pipeline data, earnings) that could drive the stock independently.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
BCAX ▼ -15.44% at T+20d
NEUTRAL call ✗ call lost -15.44% · α vs SPY -17.94% · entry $28.10 → $23.76
Next anchor: T+60d in 4d
Latest observation: T+55 -45.64% FF3 residual α
Entry anchored
Jul 13, 03:59 PM ET
via exchange tick
T+1d
+0.05%
call +0.05% · α -0.34%
$28.12
settled 3mo ago
T+5d
-3.38%
call -3.38% · α -2.09%
$27.15
settled 2mo ago
T+20d
-15.44%
call -15.44% · α -17.94%
$23.76
settled 8w ago
T+60d
—
call — · α —
—
in 4d

Price Chart

Loading chart...

Executive Summary

Three BCAX insiders, including the CEO and CFO, sold a total of ~$324K in shares over a 7-day window. The CEO's sales followed option exercises at a fraction of the market price, a routine pattern for tax planning. The total value is only ~0.02% of the $1.8B market cap, making this cluster economically trivial and non-informative.

Key Financial Metrics

Direction
selling
Total Value
$324.0K
Insiders
3

Key Facts

  • CEO Claire Mazumdar sold 10,000 shares for ~$284K after exercising options at $3.79 and $0.
  • CFO Ivan Hyep sold 830 shares for ~$25K.
  • President/COO Ryan Cohlhepp sold 536 shares for ~$16K.
  • Total cluster value of ~$324K represents ~0.02% of BCAX's $1.8B market cap.
  • All sales were open-market; no cluster buys were present.

Financial Impact

Total insider sales of ~$324K, or ~0.02% of market cap — negligible economic impact.

dilution

Risk Factors

  • Insider sales are small and routine — no elevated risk of adverse news.
  • Historical calibration shows this filing type has a negative average alpha at T+20 (-0.89%), but the tiny size of this cluster makes it noise.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BCAX-1784103345688
20 reports for BCAX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BCAX — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$24.73 $19.78▼ −20.02%▼ −20.24%$18.25 (−26.18%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$24.28 $23.20▼ −4.45%▼ −2.46%$18.25 (−24.81%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 5/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 11, 2026
7w ago
8-K
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Aug 11, 2026
7w ago
Press Release
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$28.10 $23.76▼ −15.44%▼ −17.94%$18.25 (−35.04%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$21.28 $29.68▼ −39.47%▼ −37.58%$18.25 (+14.22%)
May 26, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$21.58 $26.34▲ +22.06%▲ +23.96%$18.25 (−15.41%)
May 11, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$22.92 $20.56▼ −10.30%▼ −9.99%$18.25 (−20.35%)
Showing 10 of 20

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 15, 2026